Business Context and Reporting Period
Company: A.P. Pharma, Inc. (Note: Metadata listed "Heron Therapeutics," but the filing text identifies the registrant as A.P. Pharma, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: A specialty pharmaceutical company developing products using proprietary Biochronomer polymer-based drug delivery technology. The primary focus is the lead product candidate, APF530, a long-acting formulation of granisetron for the prevention of chemotherapy-induced nausea and vomiting (CINV). Development of other pipeline products (APF112, APF580) has been temporarily deferred to focus resources on APF530.
Key Financial Metrics
| Metric (in thousands) | 2010 | 2009 |
|---|---|---|
| Contract Revenue | $1,301 | $1,261 |
| Operating Expenses | $11,235 | $11,503 |
| Operating Loss | $(9,934) | $(10,242) |
| Net Loss | $(7,346) | $(10,028) |
| Cash and Cash Equivalents (Year End) | $2,109 | $7,593 |
| Working Capital | $941 | $6,426 |
| Accumulated Deficit | $(148,425) | $(141,079) |
Unusual Items: The 2010 results included a one-time $2.5 million gain on the sale of royalty interests (final payment from Paul Royalty Fund) and a $240,000 non-taxable government grant. Without these items, the operating loss would have been significantly higher.
Material Changes vs. Prior Period
- Liquidity Deterioration: Cash and cash equivalents decreased by approximately $5.5 million (from $7.6M to $2.1M) due to operating losses, partially offset by the royalty gain. Working capital declined from $6.4 million to $0.9 million.
- Revenue Stability: Contract revenue remained relatively flat, increasing slightly by 3% ($40k) compared to 2009. 2010 revenue was driven by a licensing agreement with Merial Limited, whereas 2009 included $1.0 million recognized from the termination of an agreement with RHEI Pharmaceuticals.
- Expense Reduction: Research and Development (R&D) expenses decreased by 7% ($532k) due to headcount reductions and the suspension of non-APF530 projects. General and Administrative (G&A) expenses increased by 7% ($264k), largely due to compensation expenses related to the resignation of the former CEO.
- Stock Price Volatility: The company faced delisting risks from The NASDAQ Capital Market due to the stock price falling below the $1.00 minimum bid price requirement for 30 consecutive days in 2010.
Guidance, Outlook, and Risks
Regulatory Status (APF530): In March 2010, the FDA issued a Complete Response Letter (CRL) to the New Drug Application (NDA), stating it could not be approved in its present form. Key issues included the dosing system, manufacturing deficiencies, and the need for a thorough QT study. The company held meetings with the FDA in February and March 2011 to address these issues. A resubmission timeline and resource requirements are pending the outcome of these discussions.
Liquidity and Going Concern: Management stated that cash resources as of December 31, 2010, were sufficient to operate only into May 2011. The company is negotiating a bridge loan and seeking additional equity, debt, or collaboration financing. The auditors have raised "substantial doubt" about the company's ability to continue as a going concern without additional financing.
Risks:
- Capital Constraints: Inability to raise capital could force the company to curtail or cease operations.
- Regulatory Approval: Failure to address FDA concerns or obtain approval for APF530 would severely impair the business.
- Delisting: Potential delisting from NASDAQ could reduce stock liquidity and access to capital markets.
- Manufacturing: Reliance on third-party manufacturers who must meet strict FDA cGMP requirements; deficiencies were noted in the CRL.
Investor Verification Checklist
- Capital Runway: Verify the status of the bridge loan negotiations and any subsequent equity/debt financing secured after the filing date to confirm operations can continue past May 2011.
- FDA Resubmission Plan: Confirm the specific timeline and cost estimates for the required QT study and manufacturing changes following the March 2011 FDA meeting.
- Delisting Status: Check current stock trading status to determine if the company has regained compliance with NASDAQ listing requirements or has been delisted.
- Discontinued Operations Liability: Review the status of the $703,000 accrued liability related to the Gross Profit Guaranty for discontinued cosmeceutical operations.